Skip to main content
. Author manuscript; available in PMC: 2019 Oct 8.
Published in final edited form as: Vaccine. 2018 Sep 14;36(42):6345–6353. doi: 10.1016/j.vaccine.2018.07.032

Figure 2:

Figure 2:

Generation of VLP-based immunogens and competition binding studies of corresponding sera. (A) Schematic representation of particle design and production. Top, plasmids used for chimeric VLP display; bottom, chemical conjugation to display b122a. (B) Competition assay between sera and monoclonal antibody b12 for binding to CD4bs on gp120. Binding was monitored by surface plasmon resonance. Pre-binding of gp120 to sera from groups 4 and 5 results in reduced binding to b12, compared to other groups indicating presence of substantial amounts of CD4bs directed antibodies in the former two groups. Sera from all groups were normalized for gp120 titers.